Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
Deal Provides Cytokinetics with Diversified Access to Capital as Company Advances Its Specialty Cardiology Franchise Deal Provides Cytokinetics with Diversified Access to Capital as Company Advances I
Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology
07:30am, Friday, 17'th May 2024
SOUTH SAN FRANCISCO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the Company will host the muscle biology-focused Contemporary Landscapes in Muscl
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024
07:30am, Wednesday, 15'th May 2024
SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten at the European Society of Cardiology Co
Statistically Significant and Clinically Meaningful Improvements Observed in Primary Efficacy Endpoint and All Secondary Endpoints; Results Consistent Across All Prespecified Subgroups
Analyses of SEQUOIA-HCM Elaborate on Dosing and Measures of Safety During Treatment with Aficamten Results from Cardiopulmonary Exercise Testing Showed Improvement in Exercise Performance were Strongl
Cytokinetics, Incorporated (CYTK) Q1 2024 Earnings Call Transcript
12:06am, Thursday, 09'th May 2024
Cytokinetics, Incorporated (NASDAQ:CYTK ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Diane Weiser - SVP of Corporate Communication and IR Robert Blum - President and
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
06:11pm, Wednesday, 08'th May 2024
Cytokinetics (CYTK) came out with a quarterly loss of $1.33 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.38 per share a year ago.
Cytokinetics Reports First Quarter 2024 Financial Results
04:00pm, Wednesday, 08'th May 2024
Primary Results and Two Additional Analyses from SEQUOIA-HCM to be Presented in a Late-Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress
Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586
07:30am, Wednesday, 08'th May 2024
Data Support Advancement to Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024
SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that CEDAR-HCM (Clinical Evaluation of Dosing with A ficamten to Reduce Obstruct
Cytokinetics to Hold Annual Meeting of Stockholders
04:00pm, Tuesday, 07'th May 2024
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 15, 2024
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
02:04pm, Tuesday, 07'th May 2024
Amid a challenging market environment, one of your best bets could be to target biotech stocks to buy. Yes, the sector can be volatile because much hinges on underlying breakthroughs.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Thursday, 02'nd May 2024
SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 30, 2024 it granted stock options to purchase an aggregate of 29,6
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:06am, Wednesday, 01'st May 2024
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will host an investor event and conference call on May 13, 2024 at 4:00 PM
